Clinical Trial Report

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, Duggal A

Clinical Ophthalmology 2019, 13:261-275

Published Date: 12 February 2019